Anti-CD22 (clone G5/44)-AcBut-CalichDMH ADC

  • Check with publisher
  • Published date: November 13, 2017
    • Shirley, New York, United States

This ADC product is comprised of an Anti-CD22 antibody (clone G5/44) conjugated via a AcBut linker to CalichDMH. The CalichDMH is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, CalichDMH binds to DNA, causes DNA damage.
Acid-labile linkers, belonging to chemically cleavable linkers, are designed based on a pH-dependent release mechanism and remain intact during systemic circulation in the blood’s neutral pH environment (pH 7.3–7.5) but to undergo hydrolysis and release drug once the ADC is internalized into mildly acidic endosomal (pH 5.0–6.5) and lysosomal (pH 4.5–5.0) compartments of the cell.
Calicheamicin,produced by prokaryotic microorganisms, are a group of DNA cleaving agents with similar structure that binds in the minor grove of DNA in a relatively sequence-specific manner.

Result 0 votes
Bella
0 votes

Useful information

  • Avoid scams by acting locally or paying with PayPal
  • Never pay with Western Union, Moneygram or other anonymous payment services
  • Don't buy or sell outside of your country. Don't accept cashier cheques from outside your country
  • This site is never involved in any transaction, and does not handle payments, shipping, guarantee transactions, provide escrow services, or offer "buyer protection" or "seller certification"

Related listings

  • Anti-CD22-DIBO-doxorubicin ADC

    Anti-CD22-DIBO-doxorubicin ADC

    Drug Development Shirley (New York) November 13, 2017 Check with publisher

    This ADC product is comprised of an anti-CD22 monoclonal antibody conjugated via a DIBO linker to a doxorubicin. The doxorubicin is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Wi...

  • Anti-CD22 (Inotuzumab)-hydrazone-Calicheamicin ADC

    Anti-CD22 (Inotuzumab)-hydrazone-Calicheamicin ADC

    Drug Development Shirley (New York) November 13, 2017 Check with publisher

    This ADC product is comprised of a Inotuzumab conjugated via a hydrazone linker to a Calicheamicin. The Calicheamicin is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the ce...

  • Anti-CD22 (Pinatuzumab)-Mc-VC-PABC-MMAE ADC

    Anti-CD22 (Pinatuzumab)-Mc-VC-PABC-MMAE ADC

    Drug Development Shirley (New York) November 13, 2017 Check with publisher

    This ADC product is comprised of a Pinatuzumab conjugated via a Mc-VC-PABC linker to a MMAE. The MMAE is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAE binds t...